Two of the three cases harbored epidermal growth factor receptor (EGFR) mutations, and MUO in EGFR-mutated NSCLC has not been previously described, suggesting a potential association with prolonged survival under targeted therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.